The ongoing randomized-controlled trial assessing the effect of tirzepatide treatment on coronary atherosclerosis progression in T2D patients, using multidetector computed tomography angiography, will provide the nature of coronary atherosclerosis progression, regression, and stabilization under the influence of dual GLP-1-GIP therapy [89]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.